0001140361-21-020643.txt : 20210611 0001140361-21-020643.hdr.sgml : 20210611 20210611161524 ACCESSION NUMBER: 0001140361-21-020643 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210610 FILED AS OF DATE: 20210611 DATE AS OF CHANGE: 20210611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN ANTHONY B CENTRAL INDEX KEY: 0001239241 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 211011451 MAIL ADDRESS: STREET 1: C/O VENROCK ASSOCIATES STREET 2: 7 BRYANT PARK, 23RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 form4.xml FORM 4 X0306 4 2021-06-10 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001239241 EVNIN ANTHONY B C/O INFINITY PHARMACEUTICALS, INC. 1100 MASSACHUSETTS AVENUE, FLOOR 4 CAMBRIDGE MA 02138 true Common Stock 2021-06-10 4 A 0 3061 3.43 A 169025 D Stock Option (right to buy) 3.43 2021-06-10 4 A 0 30000 0 A 2031-06-09 Common Stock 30000 30000 D Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 25% of such person's $42,000 annual retainer for service as a director. The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. /s/ Anthony B. Evnin 2021-06-11